What is the half-life of Abciximab?

The half-life of Abciximab is indeed around 72 hours. This long half-life is significant in the context of its pharmacological effects, as Abciximab functions as a monoclonal antibody that inhibits glycoprotein IIb/IIIa receptors on platelets, effectively reducing platelet aggregation.

Due to its extended half-life, the effects of Abciximab can last beyond the immediate clearance of the drug from the bloodstream. This is particularly useful in the setting of percutaneous coronary interventions, as it provides a prolonged antiplatelet effect, which can decrease the likelihood of thrombotic events following procedures. This characteristic can influence clinical decisions regarding the timing of surgeries or other interventions following Abciximab administration.

In contrast, shorter half-lives associated with other antiplatelet agents would require more frequent dosing to maintain therapeutic effects, which may not be as convenient or effective in certain situations.